As per the strategic distribution pact inked between the two companies, Mumbai-based Lupin will launch LG Life Sciences' Insulin Glargine, a novel insulin analogue, under the brand name BasugineTM
Drug major Lupin has inked a marketing pact with South Korea's LG Life Sciences to launch its anti-diabetes drug in India.
As per the strategic distribution pact inked between the two companies, Mumbai-based Lupin will launch LG Life Sciences' Insulin Glargine, a novel insulin analogue, under the brand name BasugineTM.
"According to the agreement, Lupin would be responsible for marketing and sales of BasugineTM in India," Lupin Ltd said in a statement.
Also read: Lupin Q1 profit jumps 56% on strong growth in US, India ops
Insulin Glargine is indicated for the treatment of adult patients with type 1 diabetes mellitus or in type 2 diabetes mellitus.
Commenting on the development, Lupin Group President, India Region Formulations, Shakti Chakraborty said: "I believe that our entry into the insulin analogue market with launch of BasugineTM is a step in the right direction."
Lupin's foray in this segment will help the company further strengthen its diabetes portfolio enabling it to grow deeper into the segment and fuel growth in the years to come, he added.
According to IMS MAT data, the overall diabetes market size within the Indian pharmaceutical Market (IPM) stood at Rs 6,032 crore, growing at 18 per cent year-on-year. The total insulin analogue market size is valued at Rs 585 crore with three year CAGR of 24 per cent while the total Glargine molecule market is estimated to be around Rs 218.5 crore.
Lupin's shares were trading 0.17 per cent down at Rs 1,175.45 apiece during afternoon trade on the BSE.
Lupin stock price
On August 06, 2014, Lupin closed at Rs 1166.30, down Rs 11.15, or 0.95 percent. The 52-week high of the share was Rs 1210.00 and the 52-week low was Rs 742.30.
The company's trailing 12-month (TTM) EPS was at Rs 65.33 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 17.85. The latest book value of the company is Rs 155.59 per share. At current value, the price-to-book value of the company is 7.50.
Anda sedang membaca artikel tentang
Lupin inks pact with S Korean firm to launch diabetes drug
Dengan url
http://kebugaranhidup.blogspot.com/2014/08/lupin-inks-pact-with-s-korean-firm-to.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Lupin inks pact with S Korean firm to launch diabetes drug
namun jangan lupa untuk meletakkan link
Lupin inks pact with S Korean firm to launch diabetes drug
sebagai sumbernya
0 komentar:
Posting Komentar